Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Ferrostatin-1 in preparation of medicine for relieving inflammatory bowel disease

A technology of inflammatory bowel disease and drugs, applied in the field of medicine, can solve the problems of disappearing curative effect and achieve the effect of improving colitis

Pending Publication Date: 2022-06-07
GUANGDONG MEDICAL UNIV +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Targeted biologic therapies are effective for many patients, but as many as 30% do not respond to initial treatment, and in as many as 50% of patients, the benefit wears off over time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Ferrostatin-1 in preparation of medicine for relieving inflammatory bowel disease
  • Application of Ferrostatin-1 in preparation of medicine for relieving inflammatory bowel disease
  • Application of Ferrostatin-1 in preparation of medicine for relieving inflammatory bowel disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106] Example 1 Mouse acute colitis model

[0107] 1. Establishment of a mouse model of acute colitis

[0108] The animal experiments involved in the establishment of the mouse acute colitis model were performed in accordance with the protocols approved by the Animal Ethics Committee of Guangdong Medical University and the committee.

[0109]Female C57 mice aged 6-8 weeks were selected and randomly divided into 3 groups, with 7 mice in each group, namely blank control group (normal diet and drinking water), model group (DSS group, dextran sulphate sodium (DSS) ), treatment group (3% (w / v) DSS+Ferrostatin-1). The blank control group drank ultrapure water normally; in order to induce acute experimental colitis, the mice in the DSS group and the treatment group drank ultrapure water for 3 days, and then freely drank drinking water containing 3% (w / v) DSS for 7 days. The fresh DSS solution was replaced every 1d; the treatment group was intraperitoneally injected with 1 mg / kg of...

Embodiment 2

[0129] Example 2 Fer-1 to H 2 O 2 Effects of treatment on IEC-6 cells

[0130] 1. Cell Culture

[0131] Rat small intestinal crypt epithelial cells (IEC-6 cells) (purchased from Hunan Fenghui Biotechnology Co., Ltd., product number: CL0172) were cultured in 10% (v / v) fetal bovine serum (Gibco, Grand Island) and 1% ( v / v) Penicillin-streptomycin (Gibco, Grand Island) in DMEM medium (Gibco, Grand Island) at 37°C and 5% CO 2 conditions for cultivation.

[0132] 2. Detection of cell viability

[0133] Divide well-grown IEC-6 cells into 5 × 10 cells 3 Cells / well were seeded in 96-well plates, and IEC-6 cells were divided into control group (without any treatment, normal culture), H 2 O 2 Treatment group (H 2 O 2 The final concentration of 400 μM) and H 2 O 2 , Fer-1 co-treatment group (H 2 O 2 The final concentration of Fer-1 was 400 μM and the final concentration of Fer-1 was 5 μM, in H 2 O 2 Before treatment, IEC-6 cells were pretreated with Fer-1 at a final concen...

Embodiment 3

[0137] Example 3 Fer-1 to H 2 O 2 Effects of reactive oxygen species on intracellular lipids in stimulated IEC-6 cells

[0138] IEC-6 cells were grown in DMEM medium containing 10% (v / v) fetal bovine serum and 1% (v / v) penicillin-streptomycin at 37°C and 5% CO 2 conditions for cultivation. Divide well-grown IEC-6 cells into 2.5 × 10 cells 5 The density of cells / well was seeded in 6-well plates, and IEC-6 cells were divided into control group (without any treatment, normal culture), H 2 O 2 Treatment group (H 2 O 2 The final concentration of 400 μM) and H 2 O 2 , Fer-1 co-treatment group (H 2 O 2 The final concentration of Fer-1 was 400 μM and the final concentration of Fer-1 was 5 μM, in H 2 O 2 Before treatment, IEC-6 cells were pretreated with Fer-1 at a final concentration of 5 μM for 30 min), 3 replicates per treatment, 37°C, 5% CO 2 Cultured for 24h under conditions; remove the cell culture supernatant in the 6-well plate, add C11-BODIPY581 / 591 lipid peroxida...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medicines, discloses application of Ferrostatin-1 in preparation of medicines for relieving inflammatory bowel diseases, and particularly discloses application of Ferrostatin-1 in preparation of medicines for treating inflammatory bowel diseases. According to the application disclosed by the invention, the effect of the Ferrostatin-1 in a mouse acute experimental colitis model is discussed by establishing the acute experimental colitis model, and a result shows that the Ferrostatin-1 can be used for improving the colitis induced by DSS and has a certain protection effect on colon tissues.

Description

technical field [0001] The invention belongs to the technical field of medicine, and particularly relates to the application of Ferrostatin-1 in the preparation of a medicine for alleviating inflammatory bowel disease. Background technique [0002] Inflammatory bowel disease (IBD) is a group of chronic nonspecific inflammations of unknown etiology that can involve the entire digestive tract, including Crohn's disease (CD) and ulcerative colitis (UC). Treatment of IBD includes non-targeted therapy and targeted biological therapy, such as aminosalicylates, glucocorticoids and immunomodulators; targeted biological therapy mainly works through one of the following mechanisms: (1) Neutralize pro-inflammatory cytokines, such as TNF-α antibodies; (2) drive the differentiation and function of specific immune cell subsets, such as IL-12 and IL-23 antibodies; (3) block signaling cascades downstream of the pathway, Such as JAK inhibitors; (4) regulation of lymphocyte migration, such a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/245A61P1/00A61P1/04A61P29/00
CPCA61K31/245A61P1/00A61P1/04A61P29/00
Inventor 罗连响赖天文曾凡云林腾雨林千文黄芳芳李晓玲罗辉丁睿林治平戚怡
Owner GUANGDONG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com